ESTABLISHMENT LABS HOLDINGS INC.
No SEC Form 4 filings for $ESTA in the last 30 days.
See all $ESTA insider activity →Establishment Labs (ESTA) reported Q2 revenue of $67.5M, up 31.7% YoY, with gross margins at 70.6%. Adjusted EBITDA turned positive at $3.7M. The company raised full-year revenue guidance to $269M-$271M. Despite operational improvements, it posted a net loss of $11.7M and faces institutional skepticism due to debt and cash burn concerns.
TD Securities predicts Establishment Labs' stock could rise due to increased demand for breast augmentation procedures driven by GLP-1 drugs. The bank maintains a buy rating and $117 price target, implying 68% upside. GLP-1 use and cosmetic surgery procedures have risen, benefiting the company's Motiva and Preservé breast implant lines. All nine analysts covering the stock recommend buying.
Establishment Labs (NASDAQ:ESTA) reported Q2 updates on its Motiva breast implant business. Outside the U.S. revenue rose 4.4% to $42.8M, with Europe up 16%. Its Minimally Invasive platform generated $12.1M revenue, nearing 15% of full-year global revenue. Gross margin improved to 70.6%. Cash was $71.2M. FDA site audits began for U.S. reconstruction; no material revenue expected until 2027.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ESTA (ESTABLISHMENT LABS HOLDINGS INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ESTA coverage spans earnings, financial news and insider activity.
No new material information; reinforces existing outlook.
Analyst upgrade and high price target suggest upside potential.
Q2 margin improvement and faster Preservé surgeon ramp support a more constructive near-term demand and gross profit outlook, while reconstruction revenue timing remains delayed to 2027.
Raised guidance and improved profitability signal accelerating demand and operating leverage, supporting a constructive near-term earnings revision backdrop.
A Schedule 13G filing signals a sizable passive/beneficial ownership position, which can affect perceived shareholder base and potential future activism risk.
AlphAI scores every news story that mentions ESTA with an AI model for sentiment and relevance, and aggregates insider trades from ESTABLISHMENT LABS HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Establishment Labs (ESTA) reported Q2 revenue of $67.5M, up 31.7% YoY, with gross margins at 70.6%. Adjusted EBITDA turned positive at $3.7M. The company raised full-year revenue guidance to $269M-$271M. Despite operational improvements, it posted a net loss of $11.7M and faces institutional skepticism due to debt and cash burn concerns.
3 min readTD Securities predicts Establishment Labs' stock could rise due to increased demand for breast augmentation procedures driven by GLP-1 drugs. The bank maintains a buy rating and $117 price target, implying 68% upside. GLP-1 use and cosmetic surgery procedures have risen, benefiting the company's Motiva and Preservé breast implant lines. All nine analysts covering the stock recommend buying.
2 min readEstablishment Labs (NASDAQ:ESTA) reported Q2 updates on its Motiva breast implant business. Outside the U.S. revenue rose 4.4% to $42.8M, with Europe up 16%. Its Minimally Invasive platform generated $12.1M revenue, nearing 15% of full-year global revenue. Gross margin improved to 70.6%. Cash was $71.2M. FDA site audits began for U.S. reconstruction; no material revenue expected until 2027.
6 min readESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Second Quarter 2026 Financial Results NEW YORK, NY, August 6, 2026 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology compa
3 min readEstablishment Labs Holdings, Inc. said a Schedule 13G filed by a shareholder group led by JW Asset Management, LLC reports beneficial ownership of 2,692,856 common shares, or 9.15% of the company’s outstanding shares (29,430,390 as of May 7, 2026). JW Partners holds 6.82% and JW Opportunities Fund holds 2.33%, with shared voting and dispositive power.
3 min readJim Cramer said Bending Spoons is a “really good” software company and recommended buying Coherent at the right level. He cited RBC’s Ken Herbert maintaining Howmet Aerospace as Outperform and raising its price target to $325. Cramer also discussed Farmers National Banc’s Q2 net income of $23.0M (39 cents/share) and AMC’s better-than-expected Q2 results.
7 min readAccording to an SEC Form 4 filed by JW Asset Management, LLC, the firm sold 90,533 shares of Establishment Labs Holdings Inc. (ESTA) in open-market transactions from May 26–28, 2026, raising about $6.64 million at a weighted average price of $73.31. The filing says it still holds 2,890,582 shares indirectly after the sale.
4 min readESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. esta-20260629 0001688757 false 0001688757 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2026 Date of Report (date of earliest ev
2 min readJW Asset Management, LLC sold 65,100 indirectly-held shares of ESTABLISHMENT LABS HOLDINGS INC. (ESTA) at $72.89 ($4.75M total) on 2026-05-28.
2 min readJW Asset Management, LLC sold 113 indirectly-held shares of ESTABLISHMENT LABS HOLDINGS INC. (ESTA) at $72.50 on 2026-05-27.
2 min read
